Ms Zita Peach appointed Non-Executive Director
Starpharma today announced the appointment of Ms Zita Peach as a Non-Executive Director.
Zita has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc.
Starpharma elevated to S&P/ASX300 index
Starpharma has received notification that it will be elevated to the S&P/ASX 300 Index, effective from 19th September.
Starpharma Presents at Macquarie Investor Event
Starpharma is one of two healthcare companies presenting at the Macquarie Bank Australia and New Zealand Annual Corporate Day in Hong Kong and Singapore.
Commencing today, the presentation to institutional investors from the Asia region will include 33 companies from Australia, from either the top 50 or 200 ASX listed companies.
Annual Report and Full Year Financial Results
Starpharma today released its annual report and financial results for the year ended 30 June 2011.
Financial Results
- Cash position at end of year $18.9M
- Net cash burn for the year $3.9M
- Cash outflows from operations $6.5M
- Reported loss $8.9M
GSK Awarded Funds to Advance Dermal Treatment with Starpharma's Dendrimers
GlaxoSmithKline (GSK), and Starpharma today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.
The funds will be used to support Starpharma’s synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product.
Starpharma terminates Reckitt Agreement and signs with Ansell
Starpharma today announced two important developments in relation to the commercialisation of its VivaGel®-coated condom.
Key Points:
- Starpharma terminates condom coating agreement with Reckitt Benckiser
- Starpharma executes condom coating agreement with Ansell
Starpharma Commences Bacterial Vaginosis Prevention Study of VivaGel®
Starpharma today announced the commencement of its Phase 2 study of VivaGel® for the prevention of bacterial vaginosis (BV), following receipt of ethics approval.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Quarterly Cash Flow Report for the period ended 30 June 2011.
The net cash burn for the year was $3.9m, resulting in a cash balance of $18.9m at 30 June 2011.
Shareholder Update: July 2011
In this issue:
› VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV
› Japanese VivaGel® condom deal secures second largest condom market in the world
› Starpharma’s Priostar dendrimers improve bestselling herbicide
› Drug delivery program delivers early-stage results in improving blockbuster chemo drug.
Partners of Bacterial Vaginosis sufferers at increased risk of HIV
Starpharma today commented on results of a study which showed that men were three times more likely to contract HIV from their female partners if the women also had bacterial vaginosis (BV) in the three months before the men became infected.